Athersys Appoints Jane Wasman as Board Chair to Drive Strategic Growth

Athersys, a leading regenerative medicine company, has announced changes to its Board of Directors following the recent Annual Meeting of Stockholders. Jane Wasman, JD, has been appointed as the new Board Chair, effective September 28, 2023. Ms. Wasman, who has been serving as a Director of the Company since November 2020, brings a wealth of expertise in strategic, operational, business development, and corporate governance matters to Athersys.

With Athersys’ multiple late-stage programs, including the Phase 3 MASTERS-2 trial evaluating MultiStem in treating ischemic stroke, Ms. Wasman’s background in the life sciences industry will be a valuable resource as the company progresses towards completing its pivotal study. Dan Camardo, Chief Executive Officer of Athersys, expressed his delight at Jane Wasman assuming the role of Board Chair and highlighted her extensive experience in the field.

Ms. Wasman is the Founder and President of JWasman Advisors, a consulting firm focused on strategic, operational, and corporate governance matters for biopharma and life sciences organizations. She also holds positions as the chair of the board of directors of Sellas Life Sciences and a member of the board of directors of Rigel Pharmaceuticals. Additionally, she co-founded and co-chairs the NY Hub of BioDirector, an organization supporting board effectiveness and diversity.

Athersys is a biotechnology company dedicated to developing therapeutic product candidates that aim to extend and enhance the quality of human life. The company’s MultiStem cell therapy product, an adult-derived “off-the-shelf” stem cell product, is being evaluated for various disease indications in the neurological, inflammatory and immune, and critical care fields. Athersys has established strategic partnerships and collaborations to advance MultiStem cell therapy towards commercialization.

Jane Wasman expressed her honor in assuming the responsibilities of Board Chair and her commitment to guiding Athersys’ initiatives to drive shareholder value. Her appointment reflects the company’s focus on leveraging her expertise to further strengthen its position in the regenerative medicine sector.

For more information about Athersys, please visit their website at www.athersys.com or follow them on Twitter at www.twitter.com/athersys.